Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Florida Kallashi

Peter J Sinclair

Julianne A Hunt

Ramzi Farah Sweis

Dooseop Kim

Christopher Francis Thompson

Cameron James Smith

Amjad Ali

Kathleen M Rupprecht

Jianming Bao

James B Doherty

Zhijian Lu

XiaoXia Qian

Wanying Sun

Shouwu Miao

Yi-Heng Chen

Petr Vachal

John E Stelmach

Guizhen Dong

Meng-Hsin Chen

Hong Li

Debra L Ondeyka

Liya Chen

Gayle E Taylor

Kake Zhao

Swaminathan R Natarajan

Joung L Goulet

Nazia Quraishi

Luping Liu

David D Wisnoski

Xingfang Hong

Jennifer Kowalchick

Samantha E Adamson

Rowena D Ruzck

Xiaoxia Qian

Jennifer E Kowalchick

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.

CETP inhibitors derived from benzoxazole arylamides

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

CETP inhibitors

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Growing community of inventors

Lawrence Harbor, NJ, United States of America

Florida Kallashi